西医一线、中医药联合西医一线治疗广泛期小细胞肺癌的研究进展  

Research progress on western medicine first-line, traditional Chinese medicine combined with western medicine first-line in the treatment of extensive stage small cell lung cancer

作　　者：李姝蒙 陈芋屹 吴桐桐 于明薇[2] 杨国旺[2] LI Shumeng;CHEN Yuyi;WU Tongtong;YU Mingwei;YANG Guowang(Graduate School,Beijing University of Chinese Medicine,Beijing100029,China;Department of Oncology,Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University,Beijing100010,China)

机构地区：[1]北京中医药大学研究生院,北京100029 [2]首都医科大学附属北京中医医院肿瘤科,北京100010

出　　处：《中国医药导报》2023年第30期43-46,共4页China Medical Herald

基　　金：国家重点研发计划项目(2018YFC1705101);国家自然科学基金面上项目(82174453);北京市自然科学基金面上项目(7222270)。

摘　　要：本文通过对近年来西医一线、中西结合一线治疗广泛期小细胞肺癌的临床研究进行归纳总结,发现相对于单纯西医一线治疗,围绕辨证论治为特点的中医药联合治疗展现出了增效减毒、延长生存期、改善中医证候、提高免疫等治疗优势,提示中医药不应只作为西医治疗失败的备用选择,应尽早介入并全程参与,形成与现代医学模式互补的中医联合治疗模式,实现效益最大化。This article summarizes clinical research on western medicine first-line,traditional Chinese medicine combined with western medicine first-line in the treatment of extensive stage small cell lung cancer in recent years.It is found that compared to the single first-line treatment of western medicine,the combination treatment of traditional Chinese medicine,characterized by differentiation of symptoms and treatment,has shown therapeutic advantages such as increasing efficacy,reducing toxicity,prolonging survival,improving traditional Chinese medicine symptoms,and enhancing immunity.It is suggested that traditional Chinese medicine should not only serve as a backup option for the failure of western medicine treatment,but should intervene as early as possible and participate throughout the entire process,forming a complementary traditional Chinese medicine combined treatment model with modern medical models,and achieving maximum benefits.

关 键 词：广泛期小细胞肺癌 化疗 免疫治疗 中医药 研究进展 

分 类 号：R734.2[医药卫生—肿瘤]